UCB (OTCMKTS:UCBJY) Downgraded to “Hold” Rating by Zacks Research

Zacks Research cut shares of UCB (OTCMKTS:UCBJY) from a strong-buy rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports.

Separately, Wolfe Research raised UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy”.

UCB Price Performance

OTCMKTS:UCBJY opened at $139.39 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. UCB has a 1 year low of $84.94 and a 1 year high of $168.76. The firm’s fifty day simple moving average is $146.61 and its 200 day simple moving average is $145.21.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.